Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This pilot study is proposed to determine the acceptability, feasibility and potential
efficacy of ketamine, a medication that modulates glutamate in the brain, as a rapid
treatment for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults
with OCD. This study will recruit 6 youth (ages 14-22) who are diagnosed with clinically
significant OCD and have failed at least one adequate trial of a Serotonin Reuptake Inhibitor
(SRI) medication and a course of Cognitive-Behavioral Therapy (CBT) (unless unable to access
or tolerate) for OCD in the past. Participants will receive a single infusion of intravenous
ketamine and be assessed at regular intervals post-infusion for up to 14 days. At the end of
the 14-day treatment phase, all participants will be offered three months of open treatment
for OCD with medication and/or CBT.